Subgroups
Bayer HealthCare
-
Tuesday - July 8, 2008
First organ-specific diagnostic agent approved in the U.S. in more than a decade:
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest:
Pharmaceuticals for the global cattle market gain further significance
Calf coccidiosis in the spotlight
-
Tuesday - July 8, 2008
XXV. World Buiatrics Congress in Budapest
Coccidiosis in cattle – an underestimated problem
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest
Photos
-
Wednesday - July 2, 2008
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market
-
Wednesday - July 2, 2008
Bayer Expands Hemophilia Portfolio
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform
-
Monday - June 30, 2008
Venous Blood Clot Prevention after Knee and Hip Replacement Surgery:
Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 patients
-
Thursday - June 26, 2008
Venous Blood Clot Prevention after Total Hip and Knee Replacement Surgery:
New England Journal of Medicine Publishes Results from Two of the Landmark Phase III RECORD Studies with Rivaroxaban
Head-to-Head trials involving over 7000 patients after Major Orthopedic Surgery / Rivaroxaban superior to Enoxaparin in Preventing Venous Blood Clots / Bleeding rates were low and comparable between the treatment arms
-
Wednesday - June 25, 2008
Venous Blood Clot Prevention after Hip Replacement Surgery:
The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
Trial involving over 2.500 patients after hip replacement surgery / Five weeks of Rivaroxaban compared to two weeks enoxaparin / Extended Rivaroxaban treatment regimen significantly more effective with comparable low bleeding rates
-
Tuesday - June 24, 2008
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected
-
Thursday - June 5, 2008
Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG
European Journalists’ Prize goes to Poland and Germany
Pawel Walewski honored for his report on the problems that cancer patients have with coping / Anahita Parastar receives prize for her report “Coma – is there a way back to life?”
-
Thursday - June 5, 2008
Geri Winkler on tour again
Sahara by bicycle
2,000 kilometers through the desert
-
Tuesday - June 3, 2008
Bayer Hemophilia Awards Program (BHAP):
Bayer HealthCare Commits US-Dollar 2.5 Million in Funding to Advance Global Hemophilia Research and Patient Care
Industry-Leading program supports cutting-edge research and clinical projects
-
Tuesday - June 3, 2008
Bayer HealthCare successfully completes acquisition of Sagmel, Inc.’s OTC Business
Bayer Consumer Care’s Presence in Eastern Europe Significantly Strengthened
-
Monday - June 2, 2008
New Nexavar® Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology (ASCO) Annual Meeting
-
Friday - May 30, 2008
Prevention of Thromboembolism after Knee Replacement Surgery:
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: “Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots”
-
Wednesday - May 28, 2008
Bundeskartellamt ends lawsuit against Bayer Vital
-
Monday - May 19, 2008
Amikacin Inhale shows promising results in Phase II Study
Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients
-
Monday - May 19, 2008
Reformulated Liquid Leukine® Now Available in the U.S.
EDTA removed from liquid formulation / Restoration of U.S. supplies of Leukine
Search
Links
Publications
Annual Report 2007
Stockholder's Newsletter
research – The Bayer Scientific Magazine
Sustainable Development Report 2007
Publications Overview
Newsletter
Events
Download Center - Selection